Current Drug Targets


Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556

Personal Subscription
Become EABM
Become Reviewer
Call for Editor

Editorial [Hot Topic: Ulcerative Colitis: A Cinderella Story (Guest Editor: Silvio Danese)] promotion: free to download

Volume:12   Issue: 10
Pp: 1372-1372
Silvio Danese
DOI: 10.2174/138945011796818207

Ulcerative Colitis: Pathogenesis

Volume:12   Issue: 10
Pp: 1373-1382
Walter Fries and Salvatore Comunale
DOI: 10.2174/138945011796818261

Genetics and Ulcerative Colitis: What are the Clinical Implications?

Volume:12   Issue: 10
Pp: 1383-1389
Anna Latiano and Vito Annese
DOI: 10.2174/138945011796818171

Natural History of Ulcerative Colitis: Current Knowledge

Volume:12   Issue: 10
Pp: 1390-1395
Lajos Sandor Kiss and Peter Laszlo Lakatos
DOI: 10.2174/138945011796818117

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

Volume:12   Issue: 10
Pp: 1396-1405
Mario Cottone, Sara Renna, Irene Modesto and Ambrogio Orlando
DOI: 10.2174/138945011796818126

Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence

Volume:12   Issue: 10
Pp: 1406-1412
Richard J. La Nauze and Miles P. Sparrow
DOI: 10.2174/138945011796818180

Methotrexate: A Drug of the Future in Ulcerative Colitis?

Volume:12   Issue: 10
Pp: 1413-1416
Franck Carbonnel
DOI: 10.2174/138945011796818252

Mucosal Healing in Ulcerative Colitis: Where do we Stand?

Volume:12   Issue: 10
Pp: 1417-1423
Gionata Fiorino, Monica Cesarini, Amedeo Indriolo and Alberto Malesci
DOI: 10.2174/138945011796818216

How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis

Volume:12   Issue: 10
Pp: 1424-1432
Raja Affendi Raja Ali and Laurence John Egan
DOI: 10.2174/138945011796818270

Biological Therapy for Ulcerative Colitis: What is after Anti-TNF

Volume:12   Issue: 10
Pp: 1433-1439
Gionata Fiorino, Monica Cesarini and Silvio Danese
DOI: 10.2174/138945011796818225

Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review

Volume:12   Issue: 10
Pp: 1440-1447
Jerome Filippi, Patrick B. Allen, Xavier Hebuterne and Laurent Peyrin-Biroulet
DOI: 10.2174/138945011796818153

Acute Severe Colitis: Infliximab and/or Cyclosporine?

Volume:12   Issue: 10
Pp: 1448-1453
Mauro Fabro, Hajnalka Szabo, Giovanni Terrosu, Claudio Avellini, Maria Tabuso, Gionata Fiorino and Dario Sorrentino
DOI: 10.2174/138945011796818234

How to Manage Pouchitis in Ulcerative Colitis?

Volume:12   Issue: 10
Pp: 1454-1461
F. Magro, S. Lopes, S. Rodrigues and I. Azevedo
DOI: 10.2174/138945011796818144

Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment?

Volume:12   Issue: 10
Pp: 1462-1466
Antonino Spinelli, Gianluca M. Sampietro, Piero Bazzi, Matteo Sacchi and Marco Montorsi
DOI: 10.2174/138945011796818199

Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis

Volume:12   Issue: 10
Pp: 1467-1477
Aranzazu Jauregui-Amezaga, Elena Ricart and Julian Panes
DOI: 10.2174/138945011796818162

Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies

Volume:12   Issue: 10
Pp: 1478-1497
Prashant Kesharwani, Virendra Gajbhiye, Rakesh K. Tekade and Narendra K. Jain
DOI: 10.2174/138945011796818135

Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit

Volume:12   Issue: 10
Pp: 1498-1512
Georgios S. Papaetis, Dora Orphanidou and Themistoklis N. Panagiotou
DOI: 10.2174/138945011796818243